Your session is about to expire
← Back to Search
Carvedilol for Heart Protection in Breast Cancer Patients
Study Summary
This trial is studying a new way to prevent heart problems in breast cancer patients who are at risk for developing them from their chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never taken BB/ACE therapy.I have a history of high blood pressure, high cholesterol, diabetes, or mild heart issues.My breast cancer has spread to other parts of my body.I am scheduled for treatment with anthracycline, trastuzumab, or pertuzumab.My heart's pumping ability is reduced.My pathology report includes HER2, estrogen, and progesterone status.I am taking heart medications other than beta-blockers or ACE inhibitors.You have second or third degree AV block.I experience heart failure symptoms with minimal activity or at rest.I have no heart symptoms or only get short of breath after walking two blocks.You are allergic to beta-blockers.I have a very slow heartbeat (<50 bpm) or very low blood pressure (<85 mmHg).My liver is severely impaired.I have a serious heart condition.I have been diagnosed with sick sinus syndrome.I am over 18 and have early stage (I-III) breast cancer with high HER2.I have moderate to severe asthma.My heart's pumping ability is normal.
- Group 1: Prophylactic Carvedilol
- Group 2: No Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment size of this research endeavor?
"This trial has closed its recruitment period and is no longer actively searching for patients. The post was initially published on April 1st 2015, with the last update made on April 14th 2022. However, there are still 2292 clinical trials recruiting participants who have cardiovascular abnormalities and 28 studies that accept Carvedilol users as volunteers."
Is this investigation presently seeking additional participants?
"Unfortunately, this research trial is not presently taking on new participants. The study was initially posted in April 2015 and has since been updated as recently as April 2022. However, if you are looking for a different clinical trial that may be suitable to your needs, there are currently 2292 studies related to cardivascular illnesses recruiting patients and 28 trials associated with Carvedilol seeking enrolment."
Could you provide information on prior research utilizing Carvedilol?
"Presently, there are 28 Carvedilol studies in progress with 7 entering Phase 3. Although Orlando, Florida is the epicentre of research for this drug, 976 clinical sites worldwide have launched trials focused on it."
Has Carvedilol been cleared by the Food and Drug Administration?
"Based on the available data, Carvedilol was rated 2 on our safety scale. This is due to this being a Phase 2 trial and thus, while there is evidence of its security, no information exists regarding efficacy."
What is Carvedilol's customary application?
"Carvedilol is a therapeutic agent that can be prescribed to address hypertensive disease and other conditions such as heart failure, hypesthesia, ventricular dysfunction, left."
Share this study with friends
Copy Link
Messenger